I am an individual and occasional investor with a passion for biotechnology and stocks. I am working as an engineer with ties to the healthcare sector.
I build investment theses based on thorough personal research and end up picking only stocks that I think hold a very high and long-term potential. I specialize in micro-cap and/or European biotechs, tracking undervalued opportunities and basing my investment choices on the deep analysis of a company's fundamentals and its long-term perspective (at least several years).
Follow me on twitter: https://twitter.com/Logribel
Awarded a 2015 "Top 50 Financial Blogger" by TipRanks.com
- Ranked #44 out of 4,408 bloggers (#106 out of 8,174 overall experts) as of 8/18/15
- Follow my ongoing coverage on TerraVia (TVIA): http://seekingalpha.com/articles?filters=szym,kevin-quon
Corey Chappell has been investing as long as any of us can remember. He started selling coins at age 13 and turned that hobby into a thriving business before he was even out of high school.
Since 2006 Corey has been investing in real estate, stocks and options. He is often the go-to-guy that friends and family call when they want to better understand their investments or what is going on in the market.
Corey is a Closing Options Analyst for 181-Close-Now and is a blogger at http://181CloseNow.com sharing his real estate and investment experience with others.
A value investor at heart, and always on the lookout for an opportunity to buy assets below their intrinsic value, Corey is an important part of the 181CloseNow team.
I am a Civil Engineer, who is married with two young kids. In 2013 I took a more active role in managing my IRA for retirement and decided to publicly share my experiences in building the portfolio as an example for the dividend growth investing strategy.
My interest in investing mostly began in 2005 when I started up an investment club with a few friends from college and has accelerated as I've been reading and learning along the way. Since then, investing and the stock market has become a passion and favorite hobby and I've enjoyed writing about stocks and sharing ideas I have here on Seeking Alpha.
My investing goals are to build a nest egg for retirement and fund college education accounts for my kids. I invest mainly in dividend paying stocks that have shown a history of consistent growth in earnings and dividend payouts.
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
Brad Thomas is a research analyst and he currently writes weekly for Forbes and Seeking Alpha where he maintains research on many publicly-listed REITs. In addition, Thomas is the Senior Analyst at iREIT Forbes and Editor of the Forbes Real Estate Investor, a monthly subscription-based newsletter.
Thomas has also been featured in Forbes Magazine, Kiplinger’s, US News & World Report, Money, NPR, Institutional Investor, GlobeStreet, and Fox Business. He was the #1 contributing analyst on Seeking Alpha in 2014 (as ranked by TipRanks) and he is currently writing a book on the legendary investor Donald Trump.
Thomas has co-authored a book (The Intelligent REIT Investor) that is available on Amazon.
Thomas received a Bachelor of Science degree in Business/Economics from Presbyterian College where he played basketball. He resides in South Carolina with his wife and kids.
I have a Masters in Engineering and have been investing and trading for 10+ years, mostly in stocks, CEFs, and options, mostly simple options strategies. I prefer value and dividend investing focusing in the financial, utility and energy sectors. I'm always looking to learn and will take requests for bank or insurance stock analysis. If you want me to do a deep dive on it, drop me a line and I'll do it.
PLEASE SEE WEBSITE FOR FULL DISCLAIMER: WWW.PUMPSTOPPER.COM
I produce high quality, original research free of charge for the public good. Please see the website for more information, and subscribe to The Pump Stopper email list to receive free, high quality research reports before the rest.
I am always committed to publishing the accurate truth. If you are involved with a company that has been mentioned in a report and find any factual errors, please submit a dispute to Seeking Alpha and it will be reviewed.
If you have any tips on companies misleading investors, please submit them on The Pump Stopper website. I always welcome collaboration and have absolute respect for your anonymity. There are multiple ways to submit documents anonymously, as outlined on the website, and I strongly recommend you send information this way.
And remember to always invest wisely.
Individual investor - with background in pharma, intellectual property, legal, regulatory, business and related strategic initiatives. President of PersisPharma LLC, since October 2014. PersisPharma is engaged in exploratory pharmaceutical research and related product development.
Sirius Capital is a Biotech Portfolio Management firm specializing in mid term investments in clinical stage biotech and pharma companies.
Our analysts combine their extensive experience in Pharma and drug development with financial management expertise to yield maximal profit to our clients.
Tim McPartland is a private investor with over 45 years of investment experience. Additionally he is the editor, and former owner, of The Yield Hunter, a website devoted to the hunt for income producing securities of all types, but in particular specializing in preferred stocks, exchange traded debt and Master Limited Partnerships.
Downtown Investment Advisory (DIA) is a Registered Investment Advisory firm based in New York that provides customized investment advisory services to individuals, charitable institutions and retirement plans. DIA currently has over $25 million under management. DIA specializes in creating custom fixed income portfolios with a core of individually selected bonds that we recommend be held to maturity. Other income assets, such as preferred stock and exchange traded debt, are also used to diversify an income portfolio. Depending on the needs and risk profile of clients, fixed income portfolios can target yields ranging from 4%-9% per annum.
DIA is licensed according to required securities regulations. DIA utilizes the services of both Charles Schwab and Interactive Brokers as a third party custodian. Clients of DIA will open and control an account at the third party custodian in their own name, and DIA nevers takes custody of client accounts.
DIA's investment manager, Salo Aizenberg, a graduate of Columbia Business School with an MBA in Finance, is a highly experienced finance and investment professional with 20 years of active investing in fixed income, equity, and alternative investments, having managed institutional portfolios exceeding $500 million.
Important disclaimer language for all articles published on Seeking Alpha, including premium Newsletter articles:
All articles published by DIA are intended as an information source for investors capable of making their own investment decisions. However, this information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. High Yield bonds are not suitable for many investors and by definition are not Investment Grade bonds and therefore carry a much higher level of risk. High Yield bonds are subject to various risks including interest rate risk, credit risk, and market risk which could result in the total loss of the investment. Past performance is no guarantee of future results. We encourage readers to consult with independent financial advisors with respect to any investment in any security mentioned. The information upon which all articles are based is obtained from sources believed to be reliable, but has not been independently verified. Therefore, DIA cannot guarantee its accuracy. Information regarding a company or security may be obsolete by the time it is published on Seeking Alpha and investors must therefore independently verify updated information regarding a company or investment. Any opinions or estimates constitute the author's best judgment as of the date of publication, and are subject to change without notice. Despite best efforts to provide quality investment information to our readers, DIA does not accept any liability or responsibility for any loss resulting from investment decisions based on information in any article. Note that DIA does not get paid or receive compensation of any kind by any company or any third party for discussing a particular company or investment in any article.
Michael Ugulini is a full-time freelance writer from the Niagara Region, Ontario, Canada. He's a business article writer and ghostwrites a daily U.S. stock market newsletter. Michael focuses his due diligence on dividend paying stocks. He has an ongoing interest in learning more about blue-chip market opportunities - as well as small cap growth stocks,. His interests include the markets, economics, and business/entrepreneurship...and baseball.
Hello, my name is Dieter Plas and I run a Belgian-based consultancy and coaching firm specialized in giving training and guidance to investors during their journey on the financial markets. We are best at writing crystal clear analysis and providing clear and understandable investment advise for our customers.
We are specialized in European markets and European shares.
Contact us via: email@example.com
I'm a retired ex-university-professor and software entrepreneur who is enjoying learning to manage a diverse portfolio focused almost entirely on producing income. I get a great deal of really actionable information from Seeking Alpha which is why I read its articles religiously. I've begun writing a series of articles for SA that chronicle my learning how to be a wise investor in the hope that other investors, particularly retirees, will be able to profit from my mistakes.
I am an independent equity research analyst and consultant. I focus on finding small-cap biotech stocks where I believe there is favorable risk / reward because of misinformation, lack of information, or a potential fundamental turnaround. I provide detail analysis for investors and investor relations companies. I also provide due diligence and advisory services to companies. Some names I write on I invest in personally and will disclose my position. Names that have hired me to provide due diligence or advisory services I will disclose a business relationship. I previously worked for Zacks Investment Research from 2003 to 2015 as a Senior Biotechnology Analyst. Prior to Zacks, I spent 1999 to 2002 managing money with Eastover Capital in Charlotte, NC where I focused on large-cap equities, specializing in healthcare, energy, and technology. Prior to joining Eastover, I worked as a research scientist for TechLab, Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases, between 1995 and 1998. I also spent a year working at the Fralin Biotechnology Center, and a year working for a cancer researcher while at Virginia Tech. I have a B.S. in Biochemistry from Virginia Tech, with a B.A in Chemistry and a minor in Math. I have a M.B.A. in Finance, with a concentration in Securities Analysis, from Wake Forest University. I hold the Chartered Financial Analyst (CFA) designation.
I am the founder of Shaun Currie Research, an independent investment research firm that offers freelance, contract-based, and performance-based investment analysis and training for investment firms, newsletters, and blogs.
I have 10 years of investment experiences which include time spent at T Rowe Price (long only), Wells Capital Management (concentrated long only), and as the Director of Research at Manalapan Oracle Capital Management (long/short equity). I am currently completing my MBA at Northwestern University's Kellogg School of Management. I graduated with a BS in Business Administration from Villanova University.
Any content on this site is NOT investment, trading, legal, or tax advice, and none of the information available through this website is intended to provide tax, legal, investment or trading advice. Nothing provided through this content whether by the owner or posted by other writers constitutes a solicitation of the purchase or sale of securities/futures.
The content on this site is intended for informational purposes only, and should never be used as investment advice. Please do your own research before making any investment decisions.
I am a recent Ivy League graduate working at a small consulting company in New York City. I genuinely enjoy researching companies and investment opportunities and come to Seeking Alpha to learn from others' perspectives and techniques. I am not a full-time trader or a financial professional, just someone who believes in investing.
I seek to liberate investors from the chains of borrowed opinions by teaching metric awareness that leads to the formation of your own opinions. I am a retail investor that gathers, processes and analyzes significantly more data than average. I share that data in my articles. I let the data do the talking. I am only taking dictation as the data tells its message.
Retired Timber Company executive with experience in both the Southeast and the Northwest. I have worked for timber companies in Alabama, Georgia, North Carolina, South Carolina, and Washington state. I have experience in timber management, wood procurement, timberland acquisitions and dispositions, and timberland consulting.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Income investing is a way of life. We earn, save and invest to produce income for monthly expenses and retirement. Dividend stocks are our passion. Finding the best dividend stocks to invest in is the journey we are on. Thanks for reading.
Like us on Facebook:
I have been fascinated by finance since the first time I picked up a copy of Wall Street Journal. I am a personal investor with more than twenty years experience. During the path toward the investment truth I have completed CFA program that significantly solidified my knowledge and helped me to develop focused, structured approach in seeking securities that have potential to produce outstanding total return results. Boris Petukh is a CFA charterholder.
Dr. Clemens Scholl was born in Salzburg, Austria. He went to school and high school in the french-speaking part of Belgium, studied physics and mathematics at the University of Cologne, Germany. He obtained a PhD in nuclear physics magna cum laude, and conducted experimental research at several national and international accelerator facilities. He has published a large number of academic papers in the field of experimental nuclear physics. Dr. Scholl has lived in Austria, Germany, England, Belgium, France and Japan. He currently lives in Germany.
Next to his scientific work, Dr. Scholl manages an investment partnership based on value investing principles. He is the CFO of a French real estate company and the general partner of Tolbiac Capital KG.